Cargando…

Recent advances in (therapeutic protein) drug development

Therapeutic protein drugs are an important class of medicines serving patients most in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, autoimmunity/inflammation, exposure to infectious...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lagassé, H.A. Daniel, Alexaki, Aikaterini, Simhadri, Vijaya L., Katagiri, Nobuko H., Jankowski, Wojciech, Sauna, Zuben E., Kimchi-Sarfaty, Chava
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000Research 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302153/ https://www.ncbi.nlm.nih.gov/pubmed/28232867 http://dx.doi.org/10.12688/f1000research.9970.1

Ejemplares similares

Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene
por: Sarachana, Tewarit, et al.
Publicado: (2015)

Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design
por: Kames, Jacob, et al.
Publicado: (2020)

Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design
por: Kames, Jacob, et al.
Publicado: (2020)

A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection
por: McGill, Joseph R., et al.
Publicado: (2022)

Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies
por: Alexaki, Aikaterini, et al.
Publicado: (2019)

Gene variants of coagulation related proteins that interact with SARS-CoV-2
por: Holcomb, David, et al.
Publicado: (2021)

HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset
por: McGill, Joseph R., et al.
Publicado: (2021)

Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
por: Lagassé, H.A. Daniel, et al.
Publicado: (2021)

A new and updated resource for codon usage tables
por: Athey, John, et al.
Publicado: (2017)

Structural, functional, and immunogenicity implications of F9 gene recoding
por: Katneni, Upendra K., et al.
Publicado: (2022)

Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

Ribosome profiling of HEK293T cells overexpressing codon optimized coagulation factor IX
por: Alexaki, Aikaterini, et al.
Publicado: (2020)

Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus
por: Hernandez, Nancy E., et al.
Publicado: (2023)

Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032]
por: Hernandez, Nancy E., et al.
Publicado: (2023)

Characterization of Conformation-Sensitive Antibodies to ADAMTS13, the von Willebrand Cleavage Protease
por: Sauna, Zuben E., et al.
Publicado: (2009)

Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population
por: Simhadri, Vijaya L., et al.
Publicado: (2018)

Splicing dysregulation contributes to the pathogenicity of several F9 exonic point variants
por: Katneni, Upendra K., et al.
Publicado: (2019)

Modified aptamers as reagents to characterize recombinant human erythropoietin products
por: Jankowski, Wojciech, et al.
Publicado: (2020)

Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4(+) T-cells
por: Simhadri, Vijaya L., et al.
Publicado: (2021)

Protocol to identify host-viral protein interactions between coagulation-related proteins and their genetic variants with SARS-CoV-2 proteins
por: Holcomb, David D., et al.
Publicado: (2022)

Distinct signatures of codon and codon pair usage in 32 primary tumor types in the novel database CancerCoCoPUTs for cancer-specific codon usage
por: Meyer, Douglas, et al.
Publicado: (2021)

The MHC Associated Peptide Proteomics assay is a useful tool for the non-clinical assessment of immunogenicity
por: Jankowski, Wojciech, et al.
Publicado: (2023)

Synonymous ADAMTS13 variants impact molecular characteristics and contribute to variability in active protein abundance
por: Jankowska, Katarzyna I., et al.
Publicado: (2022)

Sensitive measurement of single-nucleotide polymorphism-induced changes of RNA conformation: application to disease studies
por: Salari, Raheleh, et al.
Publicado: (2013)

In silico methods for predicting functional synonymous variants
por: Lin, Brian C., et al.
Publicado: (2023)

Editorial: Immunogenicity of Proteins Used as Therapeutics
por: Sauna, Zuben E., et al.
Publicado: (2020)

Aptamers as a Sensitive Tool to Detect Subtle Modifications in Therapeutic Proteins
por: Zichel, Ran, et al.
Publicado: (2012)

Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
por: Sauna, Zuben E., et al.
Publicado: (2023)

Characterization of Coding Synonymous and Non-Synonymous Variants in ADAMTS13 Using Ex Vivo and In Silico Approaches
por: Edwards, Nathan C., et al.
Publicado: (2012)

Inhibition of Multidrug Resistance by SV40 Pseudovirion Delivery of an Antigene Peptide Nucleic Acid (PNA) in Cultured Cells
por: Macadangdang, Benjamin, et al.
Publicado: (2011)

In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2
por: Laurie, Kyle, et al.
Publicado: (2021)

Analysis of 3.5 million SARS-CoV-2 sequences reveals unique mutational trends with consistent nucleotide and codon frequencies
por: Fumagalli, Sarah E., et al.
Publicado: (2023)

Role of microRNAs in Hemophilia and Thrombosis in Humans
por: Jankowska, Katarzyna I., et al.
Publicado: (2020)

Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

A Foundational Study for Normal F8-Containing Mouse Models for the miRNA Regulation of Hemophilia A: Identification and Analysis of Mouse miRNAs that Downregulate the Murine F8 Gene
por: Jankowska, Katarzyna I., et al.
Publicado: (2020)

A Single Synonymous Variant (c.354G>A [p.P118P]) in ADAMTS13 Confers Enhanced Specific Activity
por: Hunt, Ryan, et al.
Publicado: (2019)

A machine learning approach for identifying variables associated with risk of developing neutralizing antidrug antibodies to factor VIII
por: Rawal, Atul, et al.
Publicado: (2023)

Detection of Intracellular Factor VIII Protein in Peripheral Blood Mononuclear Cells by Flow Cytometry
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

Immunogenicity of Protein Therapeutics: A Lymph Node Perspective
por: Fu, Kristy, et al.
Publicado: (2020)

Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
por: Athar, Teeba, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_il02qguiri454q7b2d3neamqmp